SEATTLE, WA--(Marketwired - May 2, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, has signed an agreement with Millennium HealthCare Inc. (PINKSHEETS: MHCC) for the distribution by Millennium Medical Devices of Atossa's ForeCYTE Breast Health devices, which consist of the patented MASCT pump and ForeCYTE patient collection kits. Millennium has submitted an initial order for 10,000 ForeCYTE collection kits, which it intends to market to managed-care networks, healthcare clinics and physician practices in the New York Metro Area and Northern New Jersey.

Atossa's MASCT system is used by physicians and nurses to collect a small amount of nipple aspirate fluid for analysis by the National Reference Laboratory for Breast Health with the ForeCYTE Breast Health Test.

The ForeCYTE test, intended for the 110 million women in the U.S. ages 18-73, is a painless, quick and non-invasive procedure that can be performed in a physician's office. ForeCYTE can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight-year period before cancer can be detected by mammography or other means. Millennium HealthCare, through its wholly-owned operating subsidiaries, provides primary care physicians practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "We are extremely pleased that Millennium HealthCare will be distributing the ForeCYTE Breast Health devices to its healthcare practitioners. Millennium shares our passion about providing life-saving diagnostics to its healthcare professionals and we look forward to working closely with the Millennium team."

Chris Amandola, President of Millennium HealthCare, stated, "According to a recent American Cancer Society report, there were over 200,000 new cases of invasive breast cancer among women in 2011. Excluding cancers of the skin, breast cancer is the most common cancer among women, accounting for nearly 1 in 3 cancers diagnosed in the U.S. Our distribution channels are excited by the prospect that Atossa's non-invasive test can offer physicians a simple and cost-effective preventive care solution to their patients for the early detection of precursors to breast cancer."

Dominick Sartorio, CEO of Millennium HealthCare, commented, "Our team continues to explore the marketplace for new medical devices that can have a meaningful impact on improving patient care. Atossa Genetics' management team has done an outstanding job of advancing breast health care through their innovative medical devices and we look forward to a long relationship building together."

Just as the Pap smear has reduced cervical cancer rates by more than 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection and treatment of the precursor changes that lead to breast cancer.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

In addition to the ForeCYTE Breast Health Test, Atossa markets the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers. For additional information, please visit http://www.atossagenetics.com.

More here:
Atossa Genetics Signs Distribution Agreement With Millennium HealthCare

Comments are closed.